Research News
Donanemab, a potential new amyloid-clearing Alzheimer’s drug, has been shown to slow cognitive decline by 35% in the early stages of Alzheimer’s disease.
Blacks and Hispanics with neuropsychiatric symptoms are more likely to develop cognitive impairment, according to recent BrightFocus-funded research.
A BrightFocus-funded research team has identified how an FDA-approved antioxidant may be used to help prevent age-related macular degeneration in people with certain genetic risk factors for the disease.
The U.S. Food and Drug Administration today granted full approved of Leqembi (lecanemab-irmb) for the treatment of Alzheimer’s disease based on its ability to clear toxic amyloid from the brain.
Initial study results of an innovative glaucoma therapy involving eye implants have yielded positive results, and a Phase 2 clinical trial of this exciting potential treatment has begun.
In a finding that raises new questions about the connection between amyloid plaques and Alzheimer’s disease, a Dutch study showed people over age 100 maintained sharp minds despite having brain changes associated with dementia.
Factors that stress the body, such as obesity, can make people more likely to develop macular degeneration when they’re older, even if they’ve returned to a normal weight, new research shows.
The FDA has approved the use of atypical antipsychotic drug Rexulti (brexpiprazole) for treating agitation associated with Alzheimer’s dementia, making it the first FDA-approved treatment for Alzheimer’s agitation in the U.S.
A new BrightFocus-funded study suggests that an FDA-approved sleeping pill may slow or stop the progression of Alzheimer’s disease, promising findings that are sparking further investigation.
A BrightFocus-funded research team has some eye-opening news: They’ve used artificial intelligence to develop a model that could one day detect Alzheimer’s disease through photographs of the eye, which could lead to earlier diagnosis and treatment.
